Kukjeon Pharmaceutical Co Ltd (307750)

Currency in KRW
3,870
-45(-1.15%)
Closed·

307750 Financial Summary

Key Ratios

P/E Ratio129.12
Price/Book1.88
Debt / Equity57.49%
Return on Equity0.32%
Dividend Yield0.26%
EBITDA5.47B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of KRW (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 29.35%
Dividend Yield
0.26%
Industry Median 0.93%
Annualised payout
10.00
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 14, 2025
EPS / Forecast
18.03 / --
Revenue / Forecast
38.28B / --
EPS Revisions
Last 90 days

FAQ

What were Kukjeon Pharmaceutical's earnings for the latest quarter?

The Kukjeon Pharmaceutical EPS (TTM) is 29.35. Kukjeon Pharmaceutical reported sales of 38,284.31, net income of 888.46, and EPS of 18.03 for the latest quarter.

What was Kukjeon Pharmaceutical's net income for the latest quarter?

Kukjeon Pharmaceutical's net income for the latest quarter was 888.46.

How did Kukjeon Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 32,139.44 in the previous quarter to 38,284.31 in the latest quarter, and net income moved from -1,724.80 to 888.46 compared to the previous quarter.

What is Kukjeon Pharmaceutical's net profit margin on a TTM basis?

Kukjeon Pharmaceutical's trailing twelve months (TTM) net profit margin is 1.27%.

How does Kukjeon Pharmaceutical's debt to equity ratio compare to industry standards?

Kukjeon Pharmaceutical's total debt-to-equity ratio is 57.49%.

What is Kukjeon Pharmaceutical's return on investment on a TTM basis?

Kukjeon Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is 0.32%.

Did Kukjeon Pharmaceutical gain or lose cash last quarter?

In the latest quarter, Kukjeon Pharmaceutical's net change in cash was -35,516.47 million.

What were Kukjeon Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, Kukjeon Pharmaceutical reported total assets of 208,527.99 million and total liabilities of 82,298.47 million.

How has Kukjeon Pharmaceutical's total revenue grown this year?

Kukjeon Pharmaceutical's total revenue was 32,139.44 in the previous quarter and 38,284.31 in the latest quarter.

What is Kukjeon Pharmaceutical's gross margin on a TTM basis?

Kukjeon Pharmaceutical's trailing twelve months (TTM) gross margin is 14.81%.

What was Kukjeon Pharmaceutical's revenue per share for the latest quarter?

Kukjeon Pharmaceutical's revenue per share for the latest quarter was 14,439.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.